Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Niagen Bioscience Inc’s stock clocked out at $6.5, up 1.72% from its previous closing price of $6.39. In other words, the price has increased by $1.72 from its previous closing price. On the day, 1.1 million shares were traded. NAGE stock price reached its highest trading level at $6.61 during the session, while it also had its lowest trading level at $6.33.
Ratios:
To gain a deeper understanding of NAGE’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.07 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 24.60. For the most recent quarter (mrq), Quick Ratio is recorded 3.29 and its Current Ratio is at 4.12. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In the most recent recommendation for this company, Canaccord Genuity on May 27, 2025, initiated with a Buy rating and assigned the stock a target price of $13.
B. Riley Securities Downgraded its Buy to Neutral on August 11, 2022, whereas the target price for the stock was revised from $6 to $2.40.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 14 ’25 when Pamir Ozan bought 4,465 shares for $6.81 per share. The transaction valued at 30,406 led to the insider holds 7,372 shares of the business.
Pamir Ozan bought 2,220 shares of NAGE for $15,210 on Nov 14 ’25. The Chief Financial Officer now owns 2,220 shares after completing the transaction at $6.85 per share. On Mar 07 ’25, another insider, Lopez Carlos Luis, who serves as the SVP, General Counsel of the company, bought 273 shares for $7.86 each. As a result, the insider paid 2,146 and bolstered with 2,251 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAGE now has a Market Capitalization of 518739872 and an Enterprise Value of 459496416. As of this moment, Niagen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 26.71, and their Forward P/E ratio for the next fiscal year is 22.09. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.38. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.16 while its Price-to-Book (P/B) ratio in mrq is 7.32. Its current Enterprise Value per Revenue stands at 3.685 whereas that against EBITDA is 22.884.
Stock Price History:
The Beta on a monthly basis for NAGE is 2.34, which has changed by 0.10745239 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, NAGE has reached a high of $14.69, while it has fallen to a 52-week low of $5.17. The 50-Day Moving Average of the stock is -2.86%, while the 200-Day Moving Average is calculated to be -26.53%.
Shares Statistics:
It appears that NAGE traded 895.75K shares on average per day over the past three months and 896990 shares per day over the past ten days. A total of 79.64M shares are outstanding, with a floating share count of 52.67M. Insiders hold about 34.01% of the company’s shares, while institutions hold 39.89% stake in the company. Shares short for NAGE as of 1767139200 were 5674234 with a Short Ratio of 6.33, compared to 1764288000 on 5521464. Therefore, it implies a Short% of Shares Outstanding of 5674234 and a Short% of Float of 10.75.
Earnings Estimates
The stock of Niagen Bioscience Inc (NAGE) is currently being evaluated by 2.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $0.05, with high estimates of $0.06 and low estimates of $0.05.
Analysts are recommending an EPS of between $0.19 and $0.17 for the fiscal current year, implying an average EPS of $0.18. EPS for the following year is $0.25, with 2.0 analysts recommending between $0.27 and $0.23.
Revenue Estimates
In. The current quarter, 5 analysts expect revenue to total $31.7M. It ranges from a high estimate of $33M to a low estimate of $30.5M. As of. The current estimate, Niagen Bioscience Inc’s year-ago sales were $29.12MFor the next quarter, 5 analysts are estimating revenue of $35.44M. There is a high estimate of $36.2M for the next quarter, whereas the lowest estimate is $34M.
A total of 5 analysts have provided revenue estimates for NAGE’s current fiscal year. The highest revenue estimate was $128.6M, while the lowest revenue estimate was $126.08M, resulting in an average revenue estimate of $127.29M. In the same quarter a year ago, actual revenue was $99.6MBased on 4 analysts’ estimates, the company’s revenue will be $153.22M in the next fiscal year. The high estimate is $155M and the low estimate is $151.8M.
